Animal models of diabetes mellitus: Relevance to vascular complications

Current Pharmaceutical Design

Volumn 14, Issue 4, 2008, Pages 309-324

  Thompson, Cecil S ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Animal models; Diabetes mellitus; Macrovascular complications; Microvascular complications

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 8 QUINOLINOL; ADVANCED GLYCATION END PRODUCT; ALLOXAN; ANGIOTENSIN I; ANTIDIABETIC AGENT; ANTIFIBROTIC AGENT; CELECOXIB; DITHIZONE; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID; N METHYL DEXTRO ASPARTIC ACID; NCX 6550; NEPAFENAC; OCTREOTIDE; PIOGLITAZONE; PRAVASTATIN; PYRIDOXAMINE; ROSIGLITAZONE; SALICYLIC ACID DERIVATIVE; SIMVASTATIN; SMP 534; SOMATOSTATIN; STREPTOZOCIN; TERUTROBAN; TRANSFORMING GROWTH FACTOR BETA; UDENAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ALLOXAN DIABETES MELLITUS; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY DISEASE; BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DIET SUPPLEMENTATION; DISEASE MODEL; DRUG MECHANISM; ERECTILE DYSFUNCTION; GLUCONEOGENESIS; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MICROALBUMINURIA; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA NEOVASCULARIZATION; REVIEW; RISK FACTOR; STREPTOZOCIN DIABETES; TRANSGENIC MOUSE; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; HUMAN; METABOLISM; VASCULAR DISEASE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; VASCULAR DISEASES;

EID: 42049094276     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208783497679     Document Type: Review

References (317)

1. Ichinose K, Kawasaki E, Eguchi K. Recent advancement of understanding pathogenesis of Type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 2007; 27: 554-64.
2. Gambelunghe G, Brozzetti A, Ghaderi M, Candeloro P, Tortoioli C, Falomi A. MICA gene polymorphism in the pathogenesis of type 1 diabetes. Ann N Y Acad Sci 2007; 1110: 92-8.
3. Decker M, Hofflich H, Elias AN. Thiazotidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 2007; July 21 [Epub ahead of print].
4. Plomgaard P, Nielsen AR, Fischer CP, Mortensen OH, Broholm C, Penkowa M, et al. Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia 2007; 50: 2562-71.
5. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
6. Englegau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140: 945-50.
7. Steinbrook R. Facing the diabetes epidemic - mandatory reporting of glycosylated hemoglobin values in New York City. N Engl J Med 2006; 345: 545-8.
8. Winer N, Sewers JR. Epidemiology of diabetes. J Clin Pharmacol 2004; 44: 397-405.
9. Wong JS. Proteinuria in diabetic patients in a primary health care setting in Sarawak. Med J Malaysia 2005; 60: 146-50.
10. Garber J. Effective treatment of hypertension in patients with diabetes mellitus. Clin Cardiol 1992; 15: 715-9.
11. Borch-Johnsen K, Kremer S. Proteinuria: value as a predictor of cardiovascular mortality in insulin dependent diabetes melitus. Br Med J 1987; 294: 1651-4.
12. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9.
13. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen P. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987; 294: 1443-52.
14. Anderson S, Brenner BM. Influence of antihypertensive therapy on development and progression of diabetes glomerulopathy. Diab Care 1988; 11: 846-9.
15. Teuscher A, Schnell H, Wilson PWF. Incidence of diabetic retinopathy and relationship to baseline plasma glucose and blood pressure. Diab Care 1988; 11: 246-51.
16. Kannel WB, McGee DI. Diabetes and glucose intolerance as risk factors for cardiovascular disease. The Framingham study. Diabetes Care 1979; 2: 120-6.
17. Campbell DB, Lavielle R, Nathan C. The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract 1991; 14(Suppl 2): S21-36.
18. Setter SM, llta JL, Thams J, Campbell KK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003: 25: 2991-3026.
19. Kobayashi M. Effects of current therapeutic intervention on insulin resistance. Diabetes Obes Metab 1999; 1 Suppl 1: S32-40.
20. Panchapakesan U, Chen XM, Pollock CA. Drug insight: thiazolidinediones and diabetic nephropathy-relevance to renoprotection. Nat Clin Pract Nephrol 2005; 1: 33-43.
21. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, et al. B-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-9.
22. Ranting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922; 7: 256-71.
23. Taylor CG. Zinc, the pancreas, and diabetes: insights from rodent studies and future diredtions. Biometals 2005; 18: 305-12.
24. Kadota I. Studies on experimental diabetes produced by organic reagents. J Lab Clin Med 1950; 35: 568-91.
25. Dunn JS, McLetchie NGB. Experimental alloxan diabetes in the rat. Lancet 1943; ii: 384-7.
26. Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 1970; 22: 485-518.
27. Rossini AA, Berger M, Shadden J, Cahill GF Jr. Beta cell protection to alloxan necrosis by anomers of D-glucose. Science 1974; 183: 424.
28. Rakieten N, Rakieten ML, Nadkami MV. Studies on the diabetogenic action of streptozotocin (NSC 37919). Cancer Chemother 1963; 29: 91-8.
29. Junod A, Lambert AE, Stauffacher W, Renold AE. Diabetogenic action of streptozotocin. Proc Soc Exp Biol Med 1967; 126: 201-5.
30. Konrad RJ, Mikolaenko I, Tolar JF, Liu K, Kudlow JE. The potential mechanism of the diabetogenic action of streptozotocin: inhibition of pancreatic B-cell O-GlcNAc-selective N-acetyl-B-D-glucosaminidase. Biochem J 2001; 356: 31-41.
31. Thompson CS, Mikhailidis DP. Streptozotocin-induced ketoacidosis and non-ketonuric diabetes in the rat: useful models for drug action. J Pharm Med 1996; 6: 57-85.
32. Van der Werf,N, Kroese FG, Rozing J, Hillebrands JL. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev 2007; 23: 169-83.
33. Yoon JW, Jun HS. Viruses cause type 1 diabetes in animals. Ann N Y Acad Sci 2006; 1079: 138-46.
34. Makino S, Konimoto K, Munaoko Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese diabetic strain of mice. Exp Anim 1980; 29: 1-13.
35. Xia CO, Peng R, Qiu Y, Annamalai M, Gordon D, Clare-salzler MJ. Transfusion ofapoptotic beta-cells induce immune tolerance to beta-cell antigens and prevents type 1 diabetes in NOD mice. Diabetes 2007; 56: 2116-23.
36. Nakhooda AF, Like AA, Chappel CI, Murray FT, Marliss EB. The spontaneously diabetic Wister rat. Metabolic and morphological studies. Diabetes 1977; 26: 100-12.
37. Papaccio G, Graziano A, d'Aquino R, De Francesco F, Puca A, Pedulla M. An early but intense cytokine production within the islets may be predictive for type 1 diabetes occurrence in the Bio Breeding (BB) rat. J Cell Physiol 2006; 209: 1016-20.
38. Yang Y, Santamaria P. Lessons on autoimmune diabetes from animal models. Clin Sci 2006; 110: 627-39.
39. Conaway HH, Faas FH, Smith SD, Sanders LL. Spontaneous diabetes mellitus in the New Zealand white rabbit: physiologic characteristics. Metabolism 1981; 30: 50-6.
40. Kramer JW, Klaassen JK, Baskin DG, Prieur DJ, Rantanen NW, Robinette JD, et al. Inheritance of diabetes mellitus in Keeshond dogs. Am J Vet Res 1988; 49: 428-31.
41. Thongboonkerd V, Zheng S, McLeish KR, Epstein PN, Klein JB. Proteomic identification and immunolocalization of increased renal calbindin-D28k expression in OVE26 diabetic mice. Rev Diabet Stud 2005; 2: 19-26.
42. Sytwu HK, Lin WD, Roffler SR, Hung JT, Sung HS, Wang CH, et al. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J Autoimmun 2003; 21: 247-54.
43. Parish NM, Chandler P, Quartey-Papafio R, Simpson E, Cooke A. The effect of bone marrow and thymus chimerism between non-obese diabetic (NOD) and NOD-E transgenic mice, on the expression and prevention of diabetes. Eur J Immunol 1993; 23: 2667-75.
44. Lehuen A, Lantz O, Beaudoin L, Laloux V, Carnaud C, Bendelac A, et al. Overexpression of natural killer T cells protects Valpha 14-Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998; 188: 1831-9.
45. Kelly DJ, Buck D, Cox AJ, Zhang Y, Gilbert RE. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am J Physiol Renal Physiol 2007; 293: F565-74.
46. Kako Y, Huang LS, Yang J, Katopodis T, Ramakrishnan R, Goldberg IJ. Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice. Effects on lipoproteins and atherosclerosis. J Lipid Res 1999; 40: 2185.
47. Kanetsuna Y, Hirano K, Nagata M, Gannon MA, Takahashi K, Harris RC, et al. Characterization of diabetic nephropathy in a transgenic model of hypoinsulinemic diabetes. Am J Physiol Renal Physiol 2006; 291: F1315-22.
48. Cooperstein SJ, Watkins D. Action of toxic drugs on islet cells. In: Cooperstein SJ, Watkins D, Eds. The islets of Langerhans. New York: Academic Press, 1981: 387-425.
49. Ho RS, Aranda CG, Tilery SJ, Botelho IH, Olivieri M, Meserve C, et al. In vivo and in vitro glucose metabolism in a low dose streptozotocin rat model of non insulin dependent diabetes. In: Shafrir E, Renold AE, eds. Lessons from Animal Diabetes 2. Frontiers in diabetes research. London: Libby 1988; 288-94.
50. Bonner-Weir S, Trent DF, Weir GC. Responses of neonatal rat islets to streptozotocin; limited B cell regeneration and hyperglycaemia. Diabetes 1981; 30: 64-9.
51. Portha B, Blondel O, Serradas P, McEvory R, Giroix M-H, Kergoat M, et al. The rat models of non insulin dependent diabetes induced by neonatal streptozotocin. Diab Metab 1989; 15: 61-75.
52. Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 1998; 47: 224-9.
53. Reaven GM, Ho H. low dose streptozotocin induced diabetes in the spontaneously hypertensive rat. Metabolism 1991; 40: 335-7.
54. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois JM, et al. A new rat model of type 2 diabetes: the fat fed, streptozotocin treated rat. Metabolism 2000; 49: 1390-4.
55. Mustad VA, Demichele S, Huang YS, Mika A, Lubbers N, Berthiaume N, et al. Differential effect of n-3 polyunsaturated fatty acids on metabolic control and vascular reactivity in type 2 diabetic ob/ob mouse. Metabolism 2006; 55: 1365-74.
56. Esser KA, Su W, Matveev S, Wong V, Zeng L, McCarthy JJ, et al. Voluntary wheel running ameliorates vascular smooth muscle hypercontractility in type 2 diabetic db/db mice. Appl Physiol Nutr Metab 2007; 32: 711-20.
57. Zhu XP, Satoh J, Muto G, Muto Y, Sagara M, Takahashi K, et al. Improvement of glucose tolerance with immunomodulators on type 2 diabetic animals. Biotherapy 1996; 9: 189-97.
58. Tanimoto M, Gohda T, Kaneko S, Hagiwara S, Murakoshi M, Aoki T, et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 2007: 56: 160-7.
59. Ghanaat-Pour H, Hang Z, Lehtihet M, Sjoholm A. Global expression profiling of glucose-regulated genes in pancreatic islets of spontaneously diabetic Goto-Kakizaki rats. J Mol Endocrinol 2007; 39: 135-50.
60. Kiraly MA, Bates HE, Yue JT, Goche-Montes D, Fediuc S, Park E, et al. Attenuation of type 2 diabetes mellitus in male Zucker diabetic fatty rat: the effects of stress and non-volitional exercise. Metabolism 2007; 56: 732-44.
61. Toyota E, Ogasawara Y, Fujimoto K, Kajita T, Shigeto F, Asano T, et al. Global heterogeneity of glomerular volume distribution in early diabetic nephropathy. Kidney Int 2004; 66: 855-61.
62. Kessler J, Hehmke B, Kloting I, Kohnert KD. Relationship between the histopathology of the endocrine-exocrine pancreas parenchyma and beta-cell function in the Chinese hamster CHIG/Han subline. Pancreas 1999; 19: 89-97.
63. Takahashi A, Tabuchi M, Suzuki W, Iizuka S, Nagata M, Ikeya Y, et al. Insulin resistance and low sympathetic nerve activity in the Tsumura Suzuki obese diabetic mouse: a new model of spontaneous type 2 diabetes melitus and obesity. Metabolism 2006; 55: 1664-9.
64. Andrikopoulos S, Hoietto J. The biochemical basis of increased hepatic glucose production in a mouse model of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1995; 38: 1389-96.
65. Allen TJ, Cooper ME, Lan HY. Use of genetic mouse models in the study of diabetic nephropathy. Curr Diab Rep 2004; 4: 435-40.
66. Huang SS, Khosrof SA, Koletsky RJ, Benetz BA, Emsberger P. Characterization of retina vascular abnormalities in lean and obese spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl 1995; 22: S129-31.
67. Allan MF, Eisen EJ, Pomp D. The M16 mouse: an outbred animal model of early onset polygenic obesity and diabesity. Obes Res 2004; 12: 1397-407.
68. Miao G, Ito T, Uchikoshi F, Tanemura M, Kawamoto K, Shimada K, et al. Development of islet-like cell clusters after pancreas transplantation in the spontaneously diabetic Torri rat. Am J Transplant 2005; 5: 2360-7.
69. Kim SY, Johnson MA, McLeod DS, Alexander T, Hansen BC, Lutty GA. Neutrophils are associated with capillary closure in sponataneously diabetic monkey retinas. Diabetes 2005; 54: 1534-42.
70. Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, et al. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes 2005; 54: 1487-96.
71. Yagil C, Barakalifa R, Sapojnikov M, Wechsler A, Ben-Dor D, Weksler-Zangen S, et al. Metabolic and genomic dissection of diabetes in the Cohen rat. Physiol Genomics 2007; 29: 181-92.
72. Zoltowska M, Delvin E, Ziv E, Peretti N, Chartre M, Levy E. Impact of in vivo glycation of LDL on platelet aggregation and monocyte chemotaxis in diabetic psammomys obesus. Lipids 2004; 39: 81-5.
73. Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, Sun H, et al. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia 2004; 47: 2215-25.
74. Hainsworth DP, Katz ML, Sanders DA, Sanders DN, Wright EJ, Sturek M. Retinal capillary basement membrane thickening in a porcine model of diabetes mellitus. Comp Med 2002; 52: 523-9.
75. Miller-Lotan R, Miller B, Nakboul F, Aronson D, Asaf R, Levy AP. Retinal capillary basement membrane thickness in diabetic mice genetically modified at the haptoglobin locus. Diabetes Metab Res Rev 2007; 23: 152-6.
76. Oturai PS, Rasch R, Hasselager E, Johansen PB, Yokoyama H, Thomsen MK, et al. Effect of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats. APMIS 1996; 104: 259-64.
77. Nishi S, Ueno M, Hisaki S, Iino N, Iguchi S, Oyama Y, et al. Ultrastructural characteristics of diabetic nephropathy. Med Electron Microsc 2000; 33: 65-73.
78. Mauer SM, Michael AF, Fish AJ, Brown DM. Spontaneous immunoglobulin and complement deposition in glomeruli of diabetic rats. Lab Invest 1972; 27: 488-94.
79. Dhavers B, Etzwiler D, Michael AF. Albumin deposition in dermal capillary basement membrane in insulin-dependent diabetes mellitus. A preliminary report. Diabetes 1981; 30: 275-8.
80. Lang GE. Pharmacological treatment of diabetic retinopathy. Opthalmologica 2007; 221: 112-7.
81. Oosterhuis JA, Vink R. Fluorescein photography in diabetic retinopathy. In: Henkes H Ed, Prespectives in Ophthalmology, Excerpta Medical Foundation, Rotterdam 1968; 115-32.
82. Sosula L, Beaumont P, Hollows FC, Jonson KM. Dilatation and endothelial proliferation of retinal capillaries in streptozotocin-diabetic rats: quantitative electron microscopy. Invest Ophthalmol 1972; 11: 926-35.
83. Bek T. Glial cell involvement in vascular occlusion of diabetic retinopathy. Acta Ophthalmol Scand 1997; 75: 239-43.
84. Masuzawa K, Jesmin S, Maeda S, Zaedi S, Shimojo N, Miyauchi T, et al. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina, Exp Biol Med 2006; 231: 1090-4.
85. Zhang SX, Sima J, Wang JJ, Shao C, Fant J, Ma JX. Systemic and periocular deliveries of plasminogen kringle 5 reduce vascular leakage in rat models of oxygen-induced retinopathy and diabetes. Curr Eye Res 2005; 30: 681-9.
86. Wilkinson-Berka JL, Wraight C, Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic refinopathy. Curr Med Chem 2006; 13: 3307-17.
87. Rota R, Chiavaroli C, Garay RP, Hannaert P. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 2004; 495: 217-24.
88. Masuzawa K, Goto K, Jesmin S, Maeda S, Miyauchi T, Kaji Y, et al. An endothelin type A receptor antagonist reverses upregulated VEGF and ICAM-1 levels in streptozotocin-induced diabetic rat retina. Curr Eye Res 2006; 31: 79-89.
89. Sima J, Zhang SX, Shao C, Fant J, Ma JX. The effect of angiostatin on vascular leakage and VEGF expression in rat retina. FEBS Lett 2004; 564: 19-23.
90. Shyong MP, Lee FL, Kuo PC, Wu AC, Cheng HC, Chen SL, et al. Reduction of experimental diabetic vascular leakage by delivery of angiostatin with a recombinant adeno-associated virus vector. Mol Vis 2007; 13: 133-41.
91. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol 2003; 458: 283-9.
92. Miyahara S, Kiryu J, Yamashiro K, Miyamoto K, Hirose F, Tamura H, et al. Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. Am J Pathol 2004; 164: 1697-706,
93. Muranaka K, Yanagi Y, Tamaki Y. Usui T, Kubota N, Iriyama A, et al. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood- retinal barrier in a streptozotocin-induced diabetic model. Invest Opthalmol Vis Sci 2006; 47: 4547-52.
94. Grant MB, Caballero S Jr. The potential role of octreotide in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4: 199-203.
95. Lang GE. Treatment of diabetic retinopathy with protein kinase C subtype Beta inhibitor. Dev Ophthalmol 2007; 39: 157-65.
96. Kato N, Yashima S, Suzuki T, Nakayama Y, Jomori T. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complicat 2003; 17: 374-9.
97. Moustafa SA. Zinc might protect oxidative changes in the retina and pancreas at the early stage of diabetic rats. Toxicol Appl Pharmacol 2004; 201: 149-55.
98. Lin J, Bierhaus A, Bugert P, Dietrich N, Feng Y, Vom Hagen F, et al. Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy. Diabetologia 2006; 49: 1089-96.
99. Chung HK, Choi SM, Ahn BO, Kwak HH, Kim JH, Kim WB. Efficacy of troxerutin on streptozotocin-induced rat model in the early stage of diabetic retinopathy. Arzneimittelforschung 2005; 55: 573-80.
100. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol 2005: 511: 191-8.
101. Kowluru RA, Odcnbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004; 53: 3233-8.
102. Krady JK, Basu A, Allen CM, Xu Y, LaNoue KF, Gardner TW, et al. Minocycline reduces proinflammatory cytokine expressior, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005; 54: 1559-65.
103. Kern TS, Miller CM, Du Y, Zheng L, Mohr S, Ball SL, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metaboiism and physiology. Diabetes 2007; 56: 373-9.
104. Zheng L, Howell SJ, Hatala DA, Huang K, Kern TS. Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy. Diabetes 2007; 56: 337-45.
105. Nakamura H, Inoue T, Arakawa N, Shimizu Y, Yoshigae Y, Fujimori I, et al. Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retincipathy models. Eur J Pharmacol 2005; 512: 239-46.
106. Phipps JA, Wilkinson-Berka JL, Fletcher EL. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenoiol. Invest Ophthalmol Vis Sci 2007; 48: 927-34.
107. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Cite Res 2004; 95: 233-8.
108. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Takeuchi M, Inoue H, et al. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res 2007; 39: 92-7.
109. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51: 2826-332.
110. Rupprecht H, Piehlmeier W. Recommendations for the management of diabetic patients with nephropathy. MMW Fortschr Med 2005; 147: 43-6.
111. Thorp ML. Diabetic nephropathy: common questions. Am Fam P hysician 2005; 72: 96-9.
112. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young Type 1 (insulin dependent) diabetic patients with and without diabetic nephropathy: Incidence and risk factors. Diabetologia 1987; 30: 144-8.
113. Borch-Johnsen K, Kreiner S. Proteinuria - a predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 1987; 294: 1651-4.
114. Wi seman MJ, Viberti GC, Mackintosh D, Jarrett RJ, Keen H. Glycaemia, arterial pressure and microalbuminuria in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1984; 26: 401-5.
115. Weir MR. microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2: 581-90.
116. Mogensen CE. How to protect the kidney in diabetic patients: with special reference to IDDM. Diabetes J997; 46: S104-11.
117. Rudberg S, Osterby R. Decreasing glomerular filtration rate-an indicator of more advanced diabetic glomerulopathy in the early course of microalbuminuria in IDDM adolescents? Nephrol Dial Transplant 1997; 12: 1149-54.
118. Ellis EN, Steffes MW, Goetz FC, Sutherland DER, Mauer SM. Glomerular filtration surface in type 1 diabetes mellitus. Kidney Int 1986; 29: 889-94.
119. Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metaloproteinase-2 in diabetic rats. Chin Med J (Engl) 2006; 119: 814-21.
120. Astrup AS, Tarnow L, Rossing P, Pietraszek L, Riis Hansen P, Parving HH. Improved prognosis in type 1 diabetic patients with nephropathy: A prospective follow-up study. Kidney Int 2005; 68: 1250-7.
121. Fioretto P, Solini A. Antihypertensive treatment and multifactorial approach for renal protection in diabetes. J Am Soc Nephrol 2005; 16: S18-21.
122. Hughes DB, Britton ML. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Pharmacotherapy 2005; 25: 1602-20.
123. Lee MY, Lee EY, Lee BJ, Won CS, Koh JH, Shin JY, et al. Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. Yonsei Med J 2007; 48: 301-7.
124. Rebsomen L, Pitel S, Boubred F, Buffat C, Feuerstein JM, Raccab D, et al. C-peptide replacement improves weight gain and renal function in diabetic rats. Diabetes Metab 2006; 32: 223-8.
125. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 30904.
126. Schrijvers BF, Flyvbjerg A, Tilton RG, Lameire NE, De Vriese AS. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 2006; 21: 324-9.
127. Kakizawa H, Itoh Y, Imamura S, Matsumoto T, Ishiwata Y, Ono Y, et al. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effect of an ACE inhibiter and an angiotensin II receptor antagonist. Horm Metab Res 2004; 36; 458-64.
128. Koga, K, Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, et al. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokishima fatty rats. Mol Med 2002; 8: 591-9.
129. Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, Campbell-Thompson M, et al. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy. J Am Soc Nephrol 2007; 18: 539-50.
130. Russo LM, del Re E, Brown D, Lin HY. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor. Diabetes 2007; 56: 380-8.
131. Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, et al. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Am J Physiol Renal Physiol 2006; 290: F813-20.
132. Mifsud S, Kelly DJ, Qi W, Zhang Y, Pollock CA, Wilkinson-Berka JL, et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003; 95: 83-91.
133. Naito Y, Uchiyama K, Aoi W, Hasegawa G, Nakamura N, Yoshida N, et al. Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. Biotactors 2004; 20: 49-59.
134. Sharma S, Kulkami SK, Chopra K. Curcumin, the active principle of tunneric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006; 33: 940-5.
135. Bhatti F, Mankhey RW, Asico L, Quinn MT, Welsh WJ, Marie C. Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney. Kidney Int 2005; 67: 1371-80.
136. Davila-Esqueda ME, Martinez-Morales F. Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat. Exp Diabesity Res 2004; 5: 245-51.
137. Oktem F, Ozguner F, Yilmaz HR, Uz E, Dundar B. Melatonin reduced urinary excretion of N-acetyl-beta-D-glucosaminidase, albumin and renal oxidative markers in diabetic rats. Clin Exp Pharmacol Physiol 2006; 33: 95-101.
138. Anjaneyulu M, Chopra K Diltiazem attenuates oxidative stress in diabetic rats. Ren Fail 2005; 27: 335-44.
139. Sharma S, Arjaneyulu M, Kulkarni SK, Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006; 76: 69-75.
140. Stefek M, Tribulova N, Gajdosik A, Gajdosikova A. The pyridoindole antioxidant stobadine attenuates histochemical changes in kidney of streptozotocin-induced diabetic rats. Acta Histochem 2002; 104: 413-7.
141. Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 2007; 292: F1141-50.
142. Wu X, Zha D, Xiang G, Zhang B, Xiao SY, Jia R. Combined MMF and insulin therapy prevents renal injury in experimental diabetic rats. Cytokine 2006; 36: 229-36.
143. Utimura I, Fujihara CK, Mattar AL, Malheiros DM, Noronha IL, Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 2003; 63: 209-16.
144. Han SY, So GA, Jee YH, Han KH, Kang YS, Kim HK, et al. Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 2004; 82: 568-76.
145. Tone A, Shikata K, Sasaki M, Ohga S, Yozai K, Nishishita S, et al. Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia 2005; 48: 2402-11.
146. Yozai K, Shikata K, Sasaki M, Tone A, Ohga S, Usui H, et al. Methotraxate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol 2005; 16: 3326-38.
147. Awad AS, Huang L, Ye H, Duong ET, Bolton WK, Linden J, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol ronal Physiol 2006; 290: F828-37.
148. Qi XM, Wu GZ, Wu YG, Lin H, Shen JJ, Lin SY. Renoproductive effect of breviscapine through suprression of renal macrophage recruitment in streptozotocin-induced diabetic rats. Nephron Exp Nephrol 2006; 104: c147-57.
149. Ding SS, Qiu C, Hess P, Xi JF, Zheng N, Clozel M. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovas Pharmacol 2003; 42: 48-54.
150. Neuhofer W, Pittrow D. Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 2006; 36(Suppl 3): 78-88.
151. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007; 18: 143-54.
152. Cosenzi A, Bernobich E, Trevisan R, Milutinovic N, Berri A, Bellini G. Nephroprotective effect of bosentan in diabetic rats. J Cardiovasc Pharmacol 2003; 42: 752-6.
153. Suleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007; 59: 247-58.
154. Komers R, Lindsley JN, Oyama TT, Anderson S. Cyclooxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 2007; 34: 36-41.
155. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC. Cyclooxygenase-2 inhibitors blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002; 62: 929-39.
156. Xu S, Jiang B, Maitland KA, Bayat H, Gu J, Nadler JL, et al. The thromboxane receptor antagonist S18886 attenuates renal oxidant stross and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 2006; 55: 110-9.
157. Yamashita T, Shikata K, Matsuda M, Okada S, Ogawa D, Sugimoto H, et al. Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats. Diabetes Res Clin Pract 2002; 57: 149-61.
158. Wu YG, Lin H, Qian H, Zhao M, Qi XM, Wu GZ, et al. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Inflamm Res 2006; 55: 192-9.
159. Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, et al. Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db /db mice. Nephron Exp Nephrol 2007; 105: e45-52.
160. Murali B, Umrani DN, Goyal RK. Effect of chronic treatment with losartan on streptozotocin-induced renal dysfunction. Mol Cell Biochem. 2003; 249: 85-90.
161. Pugsley MK. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc West Pharmacol Soc 2005; 48: 35-8.
162. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005; 16: 3631-41.
163. Gross ML, Koch A, Muhlbauer B, Adamczak M, Ziebart H, Drescher K, et al. Renoprotective effect of a dopamine D3 receptor antagonist in experimental type II diabetes. Lab Invest 2006; 86: 262-74.
164. Pfeil K, Staudacher T, Luippold G. Effect of L-dopa decarboxylase inhibitor benscrazide on renal function in streptozotocin-diabetic rats. Kidney Blood Press Res 2006; 29: 43-7.
165. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, et al. Reduction of the accumulation of advanced glyeation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51: 274-82.
166. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, et al. Anti-hypertensive agents inhibits in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212-22.
167. Davis BJ, Johnston CI, Burrell LM, Burns WC, Kubota E, Cao Z, et al. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 2003; 46: 961-71.
168. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003; 52: 512-8.
169. Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 2003; 42: 456-65.
170. Wu Y, Wu G, Qi X, Lin H, Qian H, Shen J, Lin S. Protein kinase C beta inhibitor LY333531 attenuates intercellular adhesion molecule-1 and
171. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) 27 rat. Diabetes 2002; 51: 3283-9.
172. Nicholls K, Mandel TE. Advanced glycosylation end-products in experimental murinc diabetic nephropathy: effect of islet isografting and of aminoguanidine. Lab Invest 1989; 60: 486-91.
173. Figarola JL, Scott S, Loera S, Tessler C, Chu P, Weiss L, et al. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia. 2003; 46: 1140-52.
174. Figarola JL, Scott S, Locra S, Xi B, Synold T, Rahbar S. Renoprotective and lipid-lowering effects of LR compounds, novel advanced glycation end product inhibitors, in streptozotocin-induced diabetic rats. Ann N Y Acad Sci 2005; 1043: 767-76.
175. Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant 2004; 19: 3012-20.
176. Yokozawa T, Yamabe N, Cho EJ, Nakagawa T, Oowada S. A study on the effects to diabetic nephropathy of Hachimi-jio-gan in rats, Nephron Exp Nephrol 2004; 97: e38-48.
177. Yamabe N, Yokozawa T. Activity of the Chinese prescription Hachimi-jio-gan against renal damage in Otsuka Long-Evans Tokushima fatty rats: a model of human type 2 diabetes mellitus. J Pharm, Pharmacol 2006; 58: 535-45.
178. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108: 261-8.
179. Casey RG, Joyce M, Roche-Nagle G, Chen G, Bouchier-Hayes D. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. J Surg Res 2005; 123: 176-81.
180. Mooradian AD, Haas MJ. Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats. Am J Ther 2007; 14: 41-5.
181. Usui H, Shikata K, Matsuda M, Okada S, Ogawa D, Yamashita T, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant 2003; 18: 265-72.
182. Qin J, Zhang Z, Liu J, Sun L, Hu L, Cooper ME, Cao Z. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. Kidney Int 2003; 64: 565-71.
183. Mankhey RW, Bhatti F, Maric C. 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol 2005, 288: F399-405.
184. Mankhey RW, Wells CC, Bhatti F, Maric C. 17beta-Estradiol supplementation reduces tubulointerstitial fibrosis by increasing MMP activity in the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 2007; 292: R769-77.
185. Chin M, Isono M, Isshiki K, Araki S, Sugimoto T, Guo B, et al. Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. Am J Pathol 2005; 166: 1629-36.
186. Dixon A, Wells CC, Singh S, Babayan R, Maric C. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropothy. Am J Nephrol 2007; 27: 120-8.
187. Levine DZ. Hyperfiltration, nitric oxide and diabetic nephropathy. Curr Hypertens Rep 2006; 8: 153-7.
188. Gunduz Z, Canoz O, Per H, Dusunsel R, Poyrazoglu MH, Tez C, et al. The effects of pentoxifylline on diabetic renal changes in steptozotocin-induced diabetes mellitus. Ren Fail 2004; 26: 597-605.
189. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Lefebvre PV. Metabolic control may influence the increase in superoxide generation in diabetic serum. Diabetes Med 1991; 8: 540-2.
190. Hoffman D, Seftel AD, Hampel N, Resnick MI. Advanced glycation end-products qench cavernosal nitric oxide J Urol 1995; 153: 441A.
191. Zhao HJ, Wang S, Cheng H, Zhang MZ, Takahashi T, Fogo AB, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006; 17: 2664-9.
192. Bredt DS, Snyder SH: Nitric oxide: a physiological messenger molecule. Annu Rev Biochem 1994; 63: 175-95.
193. Lau DHW, Mikhailidis DP, Thompson CS. The effect of vardenafil (a PDE type 5 inhibitor) on renal function in the diabetic rabbit: a pilot study. In vivo 2007; 21: 851-854.
194. Onczato ML, Tojo A, Goto A, Fujita T. Effect of combination therapy with dipyridamole and quinapril in diabetic nephropathy. Diabetes Res Clin Pract 2003; 59: 83-92.
195. Gries FA, Koschinsky T. Diabetes and arterial disease. Diabet Med 1991; 8; S82-7.
196. Sharma V, McNeil JH. Diabetic cardiomyopathy: where are we 40 years later? Can J Cardiol 2006; 22: 305-8.
197. Wang J, Song Y, Wang Q, Kralik PM, Epstein PN. Causes and characteristics of diabetic cardiomyopathy. Rev Diadet Stud 2006; 3: 108-17.
198. Fein FS, Kornstein LB, Strobeck JE, Capasso JM, Sonnenblick EH. Altered myocardial mechanics in diabetic rats, Circ Res 1980; 47: 922-33.
199. Yu X, Tesiram YA, Towner RA, Abbott A, Patterson E, Huang S, et al. Early myocardial dysfunction in streptozotocin-induced diabetic mice: a study using in vivo magnetic resonance imaging (MRI). Cardiovasc Diabetol 2007; 6: 6-13.
200. Liang Q, Carlson EC, Donthi RV, Kralik PM, Shen X, Epstein PN. Overexpression of metallothionein reduces diabetic cardiomyopathy. Diabetes 2002; 51: 174-81.
201. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, et al. Attenuatiaon by metallothionein of early cardiac cell death via suppression of mitochondrial ocidative stress results in a prevention of diabetic cardiomyopathy. J Ara Coll Cardiol 2006; 48: 1688-97.
202. Wold LE, Ceylan-Isik AF, Fang CX, Yang X, Li SY, Sreejayan N, et al. Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radic Biol Med 2006; 40: 1419-29.
203. Wang J, Song Y, Elsherif L, Song Z, Zhou G, Prabhu SD et al. Cardiac Metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006; 113: 544-54.
204. Stefek M, Sotnikova R, Okruhlicova L, Volkovova K, Kucharska J, Gajdosik A, et al. Effect of dietary supplementation with the pyridoindole antioxidant stobadine on antioxidant state and ultrastructure of diabetic rat myocardium. Acta Diabetol 2000; 37: 111-7.
205. Muruganandan S, Gupta S, Kataria M, Lal J, Gupta PK. Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissue in rats. Toxicology 2002; 176: 165-73.
206. Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, Laragione T, et al. Antioxidant treatment attenuates hyperglycaemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 2004; 37: 959-68.
207. Xia Z, Guo Z, Nagareddy PR, Yuen V, Yeung E, McNeill JH. Antioxidant N-acetylcysteine restores myocardial Mn-SOD activity and attenuates myocardial dysfunction in diabetic rats. Eur J Pharmacol 2006; 544: 118-25.
208. Xia Z, Kuo KH, Nagareddy PR, Wang F, Guo Z, Guo T, et al. N-acetylcysteine attenuates PKCbeta2 overexpression and myocardial hypertrophy in streptozotocin-induced diabetic rats. Cardiovasc Res 2007; 73: 770-82.
209. Kaul N. Siveski-Iliskovic N, Thomas TP, Hill M, Kbaper N, Singal PK. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 1995; 11(5 Suppl): 551-4.
210. Kaul N, Siveski-Iliskovic N, Hill M, Khaper N, Seneviratne C, Singal PK. Probucol treatment reverses antioxidant and functional deficit in diabetic cardiomyopathy. Mol Cell Biochem 1996; 160-161: 283-8.
211. Ceylan-Isik AF, WuS, Li Q, Li SY, Ren J. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J Appl Physiol 2006; 100: 150-6.
212. Rösen P, Du X, Tschöpe D. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alphatocopherol? Mol Cell Biochem 1998; 188: 103-11.
213. Haidara MA, Yassin HZ, Rateb M, Ammar H, Zorkani MA. Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr Vasc Pharmacol 2006; 4: 215-27.
214. Jeremy JY, Mikhailidis DP, Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes 1983; 32: 217-21.
215. Ueno Y, Koike H, Nishio S. Beneficial effects of beraprost sodium, a stable prostacyclin analogue, in diabetic cardiomyopathy. J Cardiovasc Pharmacol 1995; 26: 603-7.
216. Elrod JW, Greer JJ, Lefer DJ. Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol Heart Circ Physiol 2007; 292: H342-7.
217. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altmann C, et al. Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J 2005; 19: 2057-9.
218. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Escher F, Bucker-Gartner C, et al. Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 2007; 56: 1834-41.
219. Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, Dhayat S, et al. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 2007; 50: 1977-86.
220. Westermann D, Rutschow S, Jager S, Linerer A, Anker S, Riad A, et al. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007; 56: 641-6.
221. Tsutsui H, Matsushima S, Kinugawa S, Ide T, Inoue N, Ohta Y, et al. Angiotensin II type 1 receptor blocker attenuates myocardial remodelling and preserved diastolic function in diabetic heart. Hypertens Res 2007; 30: 439-49.
222. Yaras N, Bilginoglu A, Vassort G, Turan B. Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockage. Am J Physiol Heart Circ Physiol 2007; 292: H912-20.
223. Liu X, Suzuki H, Sethi R, Tappia PS, Takeda N, Dhalla NS. Blockade of the renin-angiotensin system attenuates sarcolemma and sarcoplasmic reticulum remodeling in chronic diabetes. Ann N Y Acad Sci 2006; 1084: 141-54.
224. Li C, Cao L, Zeng Q, Liu X, Zhang Y, Dai T, et al. Taurine may prevent diabetic rats from developing cardiomyopathy also by downregulating angiotensin II type2 receptor expression. Cardiovasc Drugs Ther 2005; 19: 105-12.
225. Finck BN. The role of the peroxisome proliferator-activated receptor alpha pathway in pathological remodeling of the diabetic heart. Curr Opin Clin Nutr Metab Care 2004; 7: 391-6.
226. Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, et al. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev 2003; 19: 487-93.
227. Carley AN, Semeniuk LM, Shimoni Y, Aasum E, Larsen TS, Berger JP, et al. Treatment of type 2 diabetic db/db mice with a novel PPARgamma agonist improves cardiac metabolism but not contractile function. Am J Physiol Endocrinol Metab 2004; 286: E449-55.
228. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002; 51: 1507-14.
229. Candido R, Forbes JM, Thomas, MC, Thallas V, Dean RG, Burns WC, et al. A breaker of advanced glycation end proaucts attenuates diabetes-induced myocardial structural changes. Circ Res 2003; 92: 785-92.
230. Chang KC, Hsu KL, Tseng CD, Lin YD, Cho YL, Tseng YZ. Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats. Br J Pharmacol 2006; 147: 944-50.
231. Diog Y, Zou R, Judd RL, Zhong J. Endothelin-1 receptor blockade prevented the electrophysiological dysfunction in cardiac myocytes of streptozotocin-induced diabetic rats. Endocrine 2006; 30: 121-7.
232. Qi MY, Xia HJ, Dai DZ, Dai Y. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to up-regulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J Cardiovasc Pharmacol 2006; 47: 729-35.
233. Wolkart G, Stessel H, saad Z, Kirchengast M, Brunner F. Cardio-protective effects of atrasentan, an endothetin-A receptor antagonist, but not nitric oxide in diabetic mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Br J Pharmacol 2006; 148: 671-81.
234. Wolkart G, Pang X, Stessel H, Kirchengast M, Brunner F. Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats. Br J Pharmacol 2007; 151: 1187-97.
235. Shah TS, Satia MC, Gandhi TP, Bangani RA, Goyal RK. Effects of chronic nifedipine treatment on streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol 1995; 26: 6-12.
236. Broderick TL, Bailey J, Gagnon KJ, Lord SJ, Vogels CM, Westcott SA. Effect of a novel molybdenum ascorbate complex on ex vivo myocardial performance in chemical diabetes mellitus. Drugs R D 2006; 7: 119-25.
237. Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes 1997; 46: 292-300.
238. Liu TP, Juang SW, Cheng JT, Tong YC. The role of sorbitol pathway and treatment effect of aldose reductase inhibitor ONO2235 in the up-regulation of cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats. Neurosci Lett 2005; 383: 131-5.
239. Krishna KM, Gopal GS, Chalam CR, Madan K, Kumar VK, Prakash GJ, et al. The influence of sulindac on diabetic cardiomyopathy: a non-invasive evaluation by Doppler echocardiography in streptozotocin-induced diabetic rats. Vascul Pharmacol 2005; 43: 91-100.
240. Anzawa R, Seki S, Horikoshi K, Taniguchi M, Mochizuki S. Exacerbation of acidosis during ischemia and reperfusion arrhythmia in hearts from type 2 Diabetic Otsuka Long-Evans Tokushima Fatty rats. Cardiovasc Diabetol 2007; 6: 17-23.
241. Shimabukuro M, Higa S, Shinzato T, Nagamine F, Komiya I, Takasu N. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 1996; 45: 1168-73.
242. Wamhoff BR, Dixon JL, Sturek M. A torvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia. J Vasc Res 2002; 39: 208-20.
243. Adameová A, Kuzelová M, Faberová V, Svec P. Protective effect of simvastatin and VULM 1457 in ischaemic-reperfused myocardium of the diabetic-bypercholesterolemic rats. Pharmazie 2006; 61: 807-8.
244. Thompson CS, Strong P, Mikhailidis DP. Improvement of ketoacidosis in the diabetic rat after the administration of the oral antilipolytic agent GR 79236. Clin Sci 1994; 86: 593-98.
245. Gornik HL, Creager MA. Contemporary management of peripheral arterial disease: 1. Cardiovascular risk-factor modification. Cleve Clin J Med 2006; 73(Suppl 4): S30-7.
246. Bembi V, Singh S, Singh P, Aneja GK, Arya TV, Arora R. Prevalence of peripheral arterial disease in a cohort of diabetic patients. South Med J 2006; 99: 564-9.
247. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 1983; 6: 87-91.
248. Mikroulis D, Papanas N, Maltezos E, Bougioukas G. Angiogenic growth factors in the treatment of peripheral arterial disease. Curr Vasc Pharmacol 2007; 5: 195-209.
249. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001; 104, 2344-50.
250. Emanueli C, Monopoli A, Kraenkel N, Meloni M, Gadau S, Campesi I, et al. Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb ischaemia in type-1 diabetic mice. Br J Pharmacol 2007; 150: 873-82.
251. Janiak P, Lainée P, Grataloup Y, Luyt CE, Bidouard JP, Michel JB, et al. Scrotonin receptor blockade improves distal perfusion after lower limb ischemia in the fatty Zucker rat. Cardiovase Res 2002; 56: 293-302.
252. Otero P, Bonet B, Herrera E, Rabano A. Development of atherosclerosis in the diabetic BALB/c mice. Prevention with Vitamin E administration. Atherosclerosis 2005; 182: 259-65.
253. Sica V, Williams-Ignarro S, de Nigris F, D'Armiento FP, Lerman LO, Balestrieri ML, et al. Autologous bone marrow cell therapy and metabolic intervention in ischemia-induced angiogenesis in the diabetic mouse hindlimb. Cell Cycle 2006; 5: 2903-8.
254. Zúrová-Nedelcevová J, Navarová J, Drábiková K, Jancinová V, Petríková M, Bernátová I, et al. Participation of reactive oxygen species in diabetes-induced endothelial dysfunction. Neuro Endocrinol Lett 2006; 27(Suppl 2): 168-71.
255. Flack JM, Hamaty M, Staffileno BA. Renin-angiotensin-aldosterone-kinin system influences on diabetic vascular disease and cardiomyopathy. Miner Electrolyte Metab 1998; 24: 412-22.
256. Levy Z, Dvir A, Shaish A, Trestman S, Cohen H, Levkovietz H, et al. Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabefic low-density lipoprotein receptor-deficient mice. Int J Exp Diabesity Res 2003; 4: 59-64.
257. Vranes D, Cooper ME, Dilley RJ. Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies. J Vasc Res 1995; 32: 183-9.
258. Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol 2005; 96: 1579-83.
259. Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Topol EJ, et al. Administration of recombinant P-selectin glycoprotein ligand Fe fusion protein suppresses inflammation and neointimal formation in Zucker diabetic rat model. Arterioscler Thromb Vase Biol 2002; 22: 1598-603.
260. Litwak KN, Cefalu WT, Wagner JD. Chronic hyperglycemia increases arterial low-density lipoprotein metabolism and atherosclerosis in cynomolgus monkeys. Metabolism 1998; 47: 947-54.
261. Arbogast BW, Lee GM, Raymond TL. In vitro injury of porcine aortic endothelial cells by very-low-density lipoproteins from diabetic rat serum. Diabetes 1982; 31: 593-9.
262. Minnich A, Zilversmit DB. Impaired triacylglycerol catabolism in hypertriglyceridemia of the diabetic, cholesterol-fed rabbit: a possible mechanism for protection from atherosclerosis. Biochim Biophys Acta 1989; 1002: 324-32.
263. Köksoy C, Ozis E, Cakmak A, Yazgan U, Okcu-Heper A, Köksoy A, et al. Simvastatin pretreatment reduces the severity of limb ischemia in an experimental diabetes model. J Vasc Surg 2007; 45: 590-6.
264. Levi Z, Shaish A, Yacov N, Levkovitz H, Trestman S, Gerber Y, et al. Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab 2003; 5: 45-50.
265. Camejo G. PPAR agonists in the treatment of insulin resistance and associated arterial disease. Int J Clin Pract Suppl 2003; 134: 36-44.
266. Rizk NN, Rafols J, Dunbar JC. Cerebral ischemia induced apoptosis and necrosis in normal and diabetic rats. Brain Res 2005; 1053: 1-9.
267. Giorda CB. Avogaro A, Maggini M, Lombardo F, Mannucci E, Turco S, et al. Incidence and risk factors for stroks in type 2 diabetic patients: the DAI study. Stroke 2007; 38: 1154-60.
268. Kurukulasuriya LR, Govindarajan G, Sewers J. Stroke prevention in diabetes and obesity. Expert Rev Cardiovasc Ther 2006; 4: 487-502.
269. Wang GX, Li GR, Wang YD, Yang TS, Ouyang YB. Characterization of neuronal cell death in normal and diabetic rats following experimental focal cerebral ischemia. Life Sci 2001; 69: 2801-10.
270. Britton M, Rafols J, Alousi S, Dunbar JC. The effects of middle cerebral artery occlusion on central nervous system apoptotic events in normal and diabetic rats. Int J Exp Diabesity Res 2003; 4. 13-20.
271. Li ZG, Britton M, Sima AA, Dnnbar JC. Diabetes enhances apoptosis induced by cerebral ischemia. Life Sci 2004; 76: 249-62.
272. Muranyi M, Fujioka M, He Q, Han A, Yong G, Csiszar K, et al. Diabetes activates cell death pathway after transient focal cerebral ischemia. Diabetes 2003; 52: 481-6.
273. Ding C, He Q, Li PA. Activation of cell death pathway after a brief period of global ischemia in diabetic and non-diabetic animals. Exp Neurol 2004; 188: 421-9.
274. Kondo F, Asanuma M, Miyazaki I, Kondo Y, Tanaka K, Makino H, et al. Progressive cortical atrophy after forebrain ischemia in diabetic rats. Neurosci Res 2001; 39: 339-46.
275. Ding C, He Q, Li PA. Diabetes increases expression of ICAM after a brief period of cerebral ischemia. J Neuroimmunol 2005; 161: 61-7.
276. Z276 Zhang RL, Lu CZ, Ren HM, Xiao BG. Metabolic changes of arachidonic acid after cerebral ischemia-reperfusion in diabetic rats. Exp Neurol 2003; 184: 746-52.
277. Lee J, Reding M. Effects of thiazotidinediones on stroke recovery: a case- matched controlled study. Neurochem Res 2007; 32: 635-8.
278. Tureyen K, Kapadia R, Bowen KK, Satriotomo I, Liang J, Feinstein DL, et al. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007; 101: 41-56.
279. Piotrowski P, Wierzbicka K, Smiałek M. Neuronal death in the rat hippocampus in experimental diabetes and cerebral ischaemia treated with antioxidants. Folia Neuropathol 2001; 39: 147-54.
280. Aragno M, Parola S, Brignardello E, Mauro A, Tamagno E, Manti R, et al. Dehydroepiandrosterone prevents oxidative injury induced by transient ischemia/reperfusion in the brain of diabetic rats. Diabetes 2000; 49: 1924-31.
281. Arrick DM, Sharpe GM, Sun H, Mayhan WG. Diabetes-induced cerebrovascular dysfunction: role of poly(ADr-ribose) polymerase. Microvasc Res 2007; 73:4-6.
282. Kusaka I, Kusaka G, Zhou C, Ishikawa M, Nanda A, Granger DN, et al. Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. Am J Physiol Heart Circ Physiol 2004; 186: H2442-51.
283. Zimmermann GA Meistrell M 3rd, Bloom O, Cockroft KM, Bianchi M, Risucci D, et al. Neurotoxicity of advanced glycation end-products during focal stroke and reuroprotective effects of amino-guanidine. Proc Natl Acad Sci USA 1995; 92: 3744-8.
284. Bômont L, MacKenzie ET. Neuroprotection after focal cerebral ischaemia in hyperglycaemic and diabetic rats. Neurosci Lett 1995; 197: 53-6.
285. Toung TK, Hum PD, Traystman RJ, Sieber FE. Estrogen decreases infarct size after temporary focal ischemia in a genetic model of type 1 diabetes mellitus. Stroke 2000; 31: 2701-6.
286. Cakmak A, Yemişçi M, Köksoy C, Yazgan U, Dinçer D, Dalkara T. Statin pre-treatment protects brain against focal cerebral ischemia in diabetic mice. J Surg Res 2007; 138: 254-8.
287. Sakakibara Y, Mitha AP, Ayoub IA, Ogilvy CS, Maynard KI. Delayed treatment with nicotinamide (vitamin B3) reduces the infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fischer 344 rats. Brain Res 2002; 931: 68-73.
288. Dumont AS, Dumont RJ, McNeill JH, Kassell NF, Sutherland GR, Verma S. Chronic endothelin antagonism restores cerebrovascular function in diabetes. Neurosurgery 2003; 52: 653-60.
289. Bredt DS, Snyder SH. Nitric oxide: a physiological messenger molecule. Ann Rev Biochem 1994; 63: 175-95.
290. Kim N, Azadzoi KM, Goldstein I, De Tejada IS. A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J Clin Invest 1991; 88: 112-18.
291. De Tejada IS. Mechanisms for the regulation of penile smooth muscle; in Lue TF (ed): World Book of Impotence. Smith/Gordon, London 1992; 39.
292. Trigo-Rocha F, Hsu GL, Donatucci CF, Luc TF. The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic, noncholinergic, neurotransmission in canine penile erection. J Urol 1993; 149: 872-77.
293. Firoozi F, Longhurst PA, White MD: Invivo and invitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit. Br J Urol 2005; 96: 164-8.
294. Sulivan ME, Thompson CS, Dashwood MR, Khan MA, Jeremy JY, Morgan RJ, et al. Nitric oxide and penile erection: Is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res 1999; 43: 658-65.
295. Lerner SE, Melman A, Christ GJ. A review of erectile dysfunction: new insights and more questions. J Urol 1993; 149: 1246-55.
296. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006; 3: 883-91.
297. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320: 1025-30.
298. Blanco R, De Tejada IS, Goldstein I, Krime RJ, Wotiz HH, Cohen RA. Dysfunctional penile cholinergic nerves in diabetic impotent men. J Urol 1990; 144: 278-80.
299. Escrig A, Marin R, Abreu P, Gonzalez-Mora JL, Mas M. Changes in mating behaviour, erectile function and nitric oxide levels in penile corpora cavernosa in streptozotocin-diabetic rats. Biol Reprod 2002; 66: 185-9.
300. Vernet D, Cai L, Garban H, Babbitt ML, Murry FT, Rajfer J. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type 1) and BBZ/WORdp (type 2) rats with erectile dysfunction. Endocrinology 1995; 136: 5709-17.
301. Thompson CS, Mumtaz FH, Khan MA, Wallis RM, Mikhailidis DP, Morgan RJ, et al. The effect of sildenafil on corpus cavernosal smooth muscle relaxation and cyclic GMP formation in the diabetic rabbit. Eur J Pharmacol 2001; 425: 57-64.
302. Sullivan ME, Mumtaz FH, Dashwood MR, Thompson CS, Naseem KM, Bruckdorfer KR, et al. Enhanced relaxation of diabetic rabbit cavernosal smooth muscle in response to nitric oxide: potential relevance to erectile dysfunction. Int J Impot Res 2002; 14: 523-32.
303. Miller MAW, Morgan RJ, Thompson CS, Mikhailidis DP, Jeremy JY. Effects of papaverine and vasointestinal polypeptide on penile and vascular cAMP and cGMP in control and diabetic animals: an in vitro study. Int J Impot Res 1995; 7: 91-100.
304. Yamanaka M, Shirai M, Shiina H, Tanaka Y, Enokida H, Tsujimura A, et al. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in diabetic rat penile crura. J Urol 2005; 173: 318-23.
305. Shirai M, Yamanaka M, Shima H, Igawa M, Kawakami T, Ishii N, et al. Vascular endothelial growth factor restores erectile function through modulation of the insulin-like growth factor system and sex hormone receptors in diabetic rat. Biochem Biophys Res Commun 2006; 341: 755-62.
306. Pu XY, Hu LQ, Wang HP, Luo YX, Wang YCH. Improvement in erectile dysfunction after insulin-like growth factor-1 gene therapy in diabetic rats. Asian J Androl 2007; 9: 83-91.
307. Suetomi T, Hisasue S, Sato V, Tabata Y, Akaza H, Tsukamoto T. Effect of basic fibroblast growth factor incorporating gelatin microspheres on erectile function in the diabetic rat. J Urol 2005; 173: 1423-8.
308. De Young L, Yu D, Bateman RM, Brock CB. Oxidative stress and antioxidant therapy: their impact in diabetes-associated erectile dysfunction. J Androl 2004; 25: 830-6.
309. Keegan A, Cotter MA, Cameron NE. Corpus cavernosum dysfunction in diabetic rats: effect of combined alpha-lipoic acid and gamma-linolenic acid treatment. Diabetes Metab Res Rev 2001; 17: 380-6.
310. Bivalacqua TJ, Usta MF, Kendirci M, Pradhan L, Alvarez X, Champion HC, et al. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of invivo extracellular superoxide dismutase gene therapy. J Sex Med 2005; 2: 187-97.
311. Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001; 87: 402-7.
312. Usta MF, Bivalacqua TJ, Yang DY, Ramanitharan A, Sell DR, Viswanathan A, et al. The protective effect of aminoguanidine on erectile function in Streptozotocin diabetic rats. J Urol 2003; 170: 1437-42.
313. Usta MF, Kendirci M, Gur S, Foxwell NA, Bivalacqua TJ, Cellek S, et al. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in Streptozotocin-induced diabetic rats: preventive versus curative treatment. J Sex Med 2006; 3: 242-50.
314. Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A. Phosphodiesterase 5 inhibitors-drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des 2006; 12: 3459-65.
315. Ahn GJ, Sohn YS, Kang KK, Ahn BO, Kwon JW, Kang SK, et al. The effect of PDE5 inhibition on the erectile function in Streptozotocin-induced diabetic rats. Int J Impot Res 2005; 17: 134-41.
316. Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, Kwon JW, et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 2005; 28: 260-6.
317. Bivalacqua TJ, Usta MF, Champion HC, Leungwattanakij S, Dabisch PA, McNamara DB. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res 2004; 16: 21-9.